Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Time for a New Slate in Tardive Dyskinesia Research.

Blanchet PJ, Lévesque D.

Mov Disord. 2020 Feb 18. doi: 10.1002/mds.28003. [Epub ahead of print] No abstract available.

PMID:
32067258
2.

Gender and funding success.

Appel-Cresswell S, Blanchet PJ, Wysocki J, Postuma RB.

Lancet. 2019 Jun 1;393(10187):2195-2196. doi: 10.1016/S0140-6736(19)31107-9. No abstract available.

PMID:
31162073
3.

Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living.

Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Sarna J, Monchi O, Duval C.

Front Neurol. 2019 Mar 22;10:256. doi: 10.3389/fneur.2019.00256. eCollection 2019.

4.

Parkinson's disease patients experiencing peak-dose dyskinesia redistribute involuntary movements throughout their body to improve motor control.

Lebel K, Duval C, Goubault E, Bogard S, Blanchet PJ.

Parkinsonism Relat Disord. 2019 Jul;64:312-314. doi: 10.1016/j.parkreldis.2019.03.016. Epub 2019 Mar 23.

5.

Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates.

Hernandez G, Mahmoudi S, Cyr M, Diaz J, Blanchet PJ, Lévesque D.

Mov Disord. 2019 May;34(5):717-726. doi: 10.1002/mds.27630. Epub 2019 Jan 24.

PMID:
30675935
6.

Electrophysiological predictors of cognitive-behavioral therapy outcome in tic disorders.

Morand-Beaulieu S, O'Connor KP, Blanchet PJ, Lavoie ME.

J Psychiatr Res. 2018 Oct;105:113-122. doi: 10.1016/j.jpsychires.2018.08.020. Epub 2018 Sep 4.

PMID:
30219560
7.

Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.

Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Langlois M, Duval C.

J Parkinsons Dis. 2018;8(2):323-331. doi: 10.3233/JPD-181312.

8.

Chronic pain and pain processing in Parkinson's disease.

Blanchet PJ, Brefel-Courbon C.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):200-206. doi: 10.1016/j.pnpbp.2017.10.010. Epub 2017 Oct 12. Review.

PMID:
29031913
9.

Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.

Lévesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, Blanchet PJ, Lévesque D.

Neuroscience. 2017 Oct 11;361:43-57. doi: 10.1016/j.neuroscience.2017.07.068. Epub 2017 Aug 5.

PMID:
28790021
10.

P300 Source Localization Contrasts in Body-Focused Repetitive Behaviors and Tic Disorders.

Sauvé G, Morand-Beaulieu S, O'Connor KP, Blanchet PJ, Lavoie ME.

Brain Sci. 2017 Jul 1;7(7). pii: E76. doi: 10.3390/brainsci7070076.

11.

Characterization of Burning Mouth Syndrome in Patients with Parkinson's Disease.

Bonenfant D, Rompré PH, Rei N, Jodoin N, Soland VL, Rey V, Brefel-Courbon C, Ory-Magne F, Rascol O, Blanchet PJ.

J Oral Facial Pain Headache. 2016 Fall;30(4):318-322. doi: 10.11607/ofph.1691.

PMID:
27792799
12.

The Impact of a Cognitive-Behavioral Therapy on Event-Related Potentials in Patients with Tic Disorders or Body-Focused Repetitive Behaviors.

Morand-Beaulieu S, O'Connor KP, Richard M, Sauvé G, Leclerc JB, Blanchet PJ, Lavoie ME.

Front Psychiatry. 2016 May 10;7:81. doi: 10.3389/fpsyt.2016.00081. eCollection 2016.

13.

In memoriam: Paul J. Bédard, MD PhD: January 19, 1942-December 26, 2014.

Blanchet PJ, Pourcher E.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jul 3;60:132-3. Review. No abstract available.

PMID:
26153581
14.

Cognitive-behavioral therapy induces sensorimotor and specific electrocortical changes in chronic tic and Tourette's disorder.

Morand-Beaulieu S, O'Connor KP, Sauvé G, Blanchet PJ, Lavoie ME.

Neuropsychologia. 2015 Dec;79(Pt B):310-21. doi: 10.1016/j.neuropsychologia.2015.05.024. Epub 2015 May 27.

PMID:
26022060
15.

In memoriam: Paul J. Bedard, MD PhD (1942-2014).

Di Paolo T, Blanchet PJ.

Parkinsonism Relat Disord. 2015 May;21(5):429. doi: 10.1016/j.parkreldis.2015.01.014. Epub 2015 Jan 31. No abstract available.

PMID:
25737206
16.

In memoriam: Paul J. Bédard, MD PhD: January 19, 1942-December 26, 2014.

Blanchet PJ, Pourcher E.

Mov Disord. 2015 Mar;30(3):299-300. doi: 10.1002/mds.26186. Epub 2015 Feb 20. No abstract available.

PMID:
25702916
17.

Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Mahmoudi S, Lévesque D, Blanchet PJ.

Mov Disord. 2014 Aug;29(9):1125-33. doi: 10.1002/mds.25909. Epub 2014 May 16.

18.

New and emerging treatments for symptomatic tardive dyskinesia.

Rana AQ, Chaudry ZM, Blanchet PJ.

Drug Des Devel Ther. 2013 Nov 6;7:1329-40. doi: 10.2147/DDDT.S32328. eCollection 2013. Review.

19.

Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia.

Blanchet PJ, Rompré PH.

J Clin Psychopharmacol. 2014 Feb;34(1):36-9. doi: 10.1097/JCP.0b013e3182a6a2e3.

PMID:
24145218
20.

Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.

Mahmoudi S, Blanchet PJ, Lévesque D.

Eur J Neurosci. 2013 Jul;38(1):2192-8. doi: 10.1111/ejn.12198. Epub 2013 Mar 31.

21.

Relevance of animal models to human tardive dyskinesia.

Blanchet PJ, Parent MT, Rompré PH, Lévesque D.

Behav Brain Funct. 2012 Mar 9;8:12. doi: 10.1186/1744-9081-8-12. Review.

22.

Contribution of orodental status to the intensity of orofacial tardive dyskinesia: an interdisciplinary and video-based assessment.

Girard P, Monette C, Normandeau L, Pampoulova T, Rompré PH, de Grandmont P, Blanchet PJ.

J Psychiatr Res. 2012 May;46(5):684-7. doi: 10.1016/j.jpsychires.2012.02.003. Epub 2012 Mar 3.

PMID:
22386652
23.

Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: a pilot study.

Blanchet PJ, Normandeau L, Rompré PH.

Schizophr Res. 2012 May;137(1-3):230-3. doi: 10.1016/j.schres.2012.01.013. Epub 2012 Feb 4.

PMID:
22309978
24.

Dental prosthetic rehabilitation approach in tardive dyskinesia with edentulism: a case report.

Blanchet PJ, Girard P, Gauthier G, Pampoulova T, Rompré PH, de Grandmont P.

Schizophr Res. 2012 Apr;136(1-3):162-3. doi: 10.1016/j.schres.2011.07.004. Epub 2011 Jul 27. No abstract available.

PMID:
21798717
25.

Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease.

Tremblay PL, Bedard MA, Langlois D, Blanchet PJ, Lemay M, Parent M.

Exp Brain Res. 2010 Sep;205(3):375-85. doi: 10.1007/s00221-010-2372-6. Epub 2010 Aug 3.

PMID:
20680249
26.

Movement irregularities in atypical parkinsonian syndromes.

Philibert M, Richer F, Blanchet PJ, Chouinard S, Dubarry AS, Fimbel E.

Parkinsonism Relat Disord. 2009 Aug;15(7):542-5. doi: 10.1016/j.parkreldis.2008.11.004. Epub 2008 Dec 21.

PMID:
19103504
27.

Motor sequence learning in primate: role of the D2 receptor in movement chunking during consolidation.

Tremblay PL, Bedard MA, Levesque M, Chebli M, Parent M, Courtemanche R, Blanchet PJ.

Behav Brain Res. 2009 Mar 2;198(1):231-9. doi: 10.1016/j.bbr.2008.11.002. Epub 2008 Nov 11.

PMID:
19041898
28.

Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects.

Blanchet PJ, Popovici R, Guitard F, Rompré PH, Lamarche C, Lavigne GJ.

Mov Disord. 2008 Oct 15;23(13):1837-42. doi: 10.1002/mds.22102.

PMID:
18759358
29.

Diffusion-weighted imaging and magnetization transfer imaging of tardive and edentulous orodyskinesia.

Khiat A, Kuznetsov Y, Blanchet PJ, Boulanger Y.

Mov Disord. 2008 Jul 15;23(9):1281-5. doi: 10.1002/mds.22081.

PMID:
18512744
30.

Postural sway and effect of levodopa in early Parkinson's disease.

Beuter A, Hernández R, Rigal R, Modolo J, Blanchet PJ.

Can J Neurol Sci. 2008 Mar;35(1):65-8.

PMID:
18380279
31.

Sensorimotor adaptation in Parkinson's disease: evidence for a dopamine dependent remapping disturbance.

Paquet F, Bedard MA, Levesque M, Tremblay PL, Lemay M, Blanchet PJ, Scherzer P, Chouinard S, Filion J.

Exp Brain Res. 2008 Feb;185(2):227-36. Epub 2007 Oct 24.

PMID:
17957363
32.

Raclopride-induced motor consolidation impairment in primates: role of the dopamine type-2 receptor in movement chunking into integrated sequences.

Levesque M, Bedard MA, Courtemanche R, Tremblay PL, Scherzer P, Blanchet PJ.

Exp Brain Res. 2007 Oct;182(4):499-508. Epub 2007 Jul 26.

PMID:
17653704
33.

Proton magnetic resonance spectroscopy study of dyskinesia patients.

Kuznetsov Y, Khiat A, Blanchet PJ, Boulanger Y.

Mov Disord. 2007 May 15;22(7):957-62.

PMID:
17377925
34.

Characterization of subclinical tremor in Parkinson's disease.

Beuter A, Barbo E, Rigal R, Blanchet PJ.

Mov Disord. 2005 Aug;20(8):945-50.

PMID:
15806574
35.

Effect of amantadine on motor memory consolidation in humans.

Hadj Tahar A, Blanchet PJ, Doyon J.

Behav Pharmacol. 2005 Mar;16(2):107-12.

PMID:
15767846
36.

Oral dyskinesia: a clinical overview.

Blanchet PJ, Rompré PH, Lavigne GJ, Lamarche C.

Int J Prosthodont. 2005 Jan-Feb;18(1):10-9. Review.

PMID:
15754887
37.

Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal.

Blanchet PJ, Abdillahi O, Beauvais C, Rompré PH, Lavigne GJ.

Mov Disord. 2004 Aug;19(8):892-6.

PMID:
15300653
38.

Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.

Blanchet PJ, Calon F, Morissette M, Hadj Tahar A, Bélanger N, Samadi P, Grondin R, Grégoire L, Meltzer L, Di Paolo T, Bédard PJ.

Parkinsonism Relat Disord. 2004 Jul;10(5):297-304. Review.

PMID:
15196509
39.

Motor-learning impairment by amantadine in healthy volunteers.

Hadj Tahar A, Blanchet PJ, Doyon J.

Neuropsychopharmacology. 2004 Jan;29(1):187-94.

40.

Complications of a trophic xenotransplant approach in parkinsonian monkeys.

Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):607-12.

PMID:
12787846
41.

Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons.

van den Munckhof P, Luk KC, Ste-Marie L, Montgomery J, Blanchet PJ, Sadikot AF, Drouin J.

Development. 2003 Jun;130(11):2535-42.

42.

Antipsychotic drug-induced movement disorders.

Blanchet PJ.

Can J Neurol Sci. 2003 Mar;30 Suppl 1:S101-7. Review.

PMID:
12691483
43.

The fluctuating Parkinsonian patient--clinical and pathophysiological aspects.

Blanchet PJ.

Can J Neurol Sci. 2003 Mar;30 Suppl 1:S19-26. Review.

PMID:
12691473
44.

Renaissance of amantadine in the treatment of Parkinson's disease.

Blanchet PJ, Metman LV, Chase TN.

Adv Neurol. 2003;91:251-7. Review. No abstract available.

PMID:
12442683
45.

Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.

Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):127-38.

PMID:
11853103
46.

Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model.

Blanchet PJ, Calon F, Morissette M, Goulet M, Grondin R, Lévesque D, Bédard PJ, Di Paolo T.

Adv Neurol. 2001;86:337-44. No abstract available.

PMID:
11553994
47.

Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism.

Lavigne GJ, Soucy JP, Lobbezoo F, Manzini C, Blanchet PJ, Montplaisir JY.

Clin Neuropharmacol. 2001 May-Jun;24(3):145-9.

PMID:
11391125
48.

Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.

Calon F, Lavertu N, Lemieux AM, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.

Synapse. 2001 Jun 1;40(3):225-34.

PMID:
11304760
49.

Dopamine-receptor stimulation: biobehavioral and biochemical consequences.

Calon F, Hadj Tahar A, Blanchet PJ, Morissette M, Grondin R, Goulet M, Doucet JP, Robertson GS, Nestler E, Di Paolo T, Bédard PJ.

Trends Neurosci. 2000 Oct;23(10 Suppl):S92-100.

PMID:
11052226
50.

125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.

Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.

Exp Neurol. 2000 May;163(1):191-9.

PMID:
10785458

Supplemental Content

Loading ...
Support Center